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The overlapping clinical and neuropathologic features between late-onset apparently sporadic Alz-
heimer’s disease (LOAD), familial Alzheimer’s disease (FAD), and other neurodegenerative dementias
(frontotemporal dementia, corticobasal degeneration, progressive supranuclear palsy, and Creutzfeldt-
Jakob disease) raise the question of whether shared genetic risk factors may explain the similar
phenotype among these disparate disorders. To investigate this intriguing hypothesis, we analyzed rare
coding variability in 6 Mendelian dementia genes (APP, PSEN1, PSEN2, GRN,MAPT, and PRNP), in 141 LOAD
patients and 179 elderly controls, neuropathologically proven, from the UK. In our cohort, 14 LOAD cases
(10%) and 11 controls (6%) carry at least 1 rare variant in the genes studied. We report a novel variant in
PSEN1 (p.I168T) and a rare variant in PSEN2 (p.A237V), absent in controls and both likely pathogenic. Our
ﬁndings support previous studies, suggesting that (1) rare coding variability in PSEN1 and PSEN2 may
inﬂuence the susceptibility for LOAD and (2) GRN, MAPT, and PRNP are not major contributors to LOAD.
Thus, genetic screening is pivotal for the clinical differential diagnosis of these neurodegenerative
dementias.
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Y license.1. Introduction
Alzheimer’s disease (AD) (OMIM #104310) is the most common
cause of progressive dementia in the elderly individuals. Aging and
genetic factors play a pivotal role for the disease development. AD
incidence increases exponentially from the age of 65 years (1.5%
affected) to 80 years and older (30% affected). Twin studies have
shown that AD heritability ranges between 60% and 80% (Bergem
et al., 1997; Gatz et al., 2006; Raiha et al., 1996). Fully penetrant
mutations in amyloid precursor protein (APP) and presenilins
(PSEN1 and PSEN2) are known to cause familial autosomal domi-
nant AD. The APOE ε4 allele is the main risk factor for apparently
sporadic AD. In the last 5 years, genome-wide association studies
(GWASs) identiﬁed several loci, harboring common variants with
low risk effect size (OR: 1.2e1.5) (Harold et al., 2009; Hollingworth
C. Sassi et al. / Neurobiology of Aging 35 (2014) 2881.e1e2881.e62881.e2et al., 2011; Lambert et al., 2009; Lambert et al., 2013; Naj et al.,
2011; Seshadri et al., 2010).
Recently, next generation sequencing has led to enormous
progress in AD genetics, with the discovery of 2 rare signiﬁcant risk
factors, mapping to TREM2 (p.R47H) and PLD3 (p.V232M), and a
very rare protective variant in APP (p.A637T) (Cruchaga et al., 2013;
Guerreiro et al., 2013; Jonsson et al., 2012). In addition, C9orf72
repeat expansion has been reported in a few patients with clinical
AD (Majounie et al., 2012).
The overlapping clinical and neuropathologic features between
AD and other neurodegenerative dementias (frontotemporal de-
mentia [FTD], corticobasal degeneration [CBD], progressive supra-
nuclear palsy [PSP], and Creutzfeldt-Jakob disease [CJD]) lead to a
misdiagnosis in 17%e30% of AD cases (Beach et al., 2012). This raises
the question of whether genetic risk factors relevant in such de-
mentias may play a role in late-onset Alzheimer’s disease (LOAD).
GWASs have shown that common noncoding variability in
Mendelian dementia genes (APP, PSEN1, PSEN2, MAPT, GRN, and
PRNP) does not inﬂuence susceptibility to AD. By contrast, a
growing body of evidence highlighted the signiﬁcant role of rare
coding variants in PSEN1 in LOAD (Benitez et al., 2013; Cruchaga
et al., 2012). Thus, to test the hypothesis that rare coding vari-
ability in genes relevant for familial Alzheimer’s disease (FAD) and
other types of dementia (APP, PSEN1, PSEN2, MAPT, GRN, and PRNP)
may underlie LOAD pathogenesis, we have analyzed exome
sequencing data, in a British cohort composed of 141 LOAD cases
without any apparent family history and 179 elderly controls au-
topsy proven.
2. Methods
2.1. Cases and controls
Our cohort was composed of 141 independent LOAD (age at
onset 65 years) cases and 179 elderly (>60 years) unrelated
controls, neuropathologically conﬁrmed. These patients were
referred as apparently sporadic LOAD cases.
All the patients and controls were Caucasian, mostly from the
UK (London, Manchester, Nottingham, and Edinburgh) and to a
lesser extent from North America. The average age at diagnosis was
76.7 years (range 65e97 years) for the LOAD patients and the mean
age of ascertainment was 78 years (range 60e102 years) for the
controls (Table 1).
Written informed consent was obtained for each individual and
the study was approved by the appropriate institutional review
boards.
2.2. Exome sequencing
Library preparation for next-generation sequencing was per-
formed according to the NimbleGen (Roche NimbleGen v2) and
TruSeq (Illumina) sample-preparationprotocols. DNA libraries were
then hybridized to exome-capture probes with NimbleGen SeqCap
EZ Human Exome Library, version 2.0 (Roche NimbleGen) or TruSeq
(Illumina). Each capture method covers the APP, PSEN1, PSEN2, GRN,
MAPT, and PRNP loci. Exome-enriched libraries were sequenced on
the Illumina HiSeq 2000 using 2  100 bp paired end read cycles.Table 1
Cohort
Cohort n Diagnosis Sequencing str
LOAD CASES 141 Clinical and neuropathologic Exome sequen
CONTROLS 179 Clinical and neuropathologic Exome sequen
Key: LOAD, late-onset Alzheimer’s disease; SD, standard deviation.2.3. Bioinformatics
Sequence alignment and variant calling were performed against
the reference human genome (UCSC hg19). Paired end sequence
reads (2  100 bp paired end read cycles) were aligned using the
Burrows-Wheeler aligner (Li and Durbin, 2009). Format conversion
and indexing were performed with Picard (www.picard.
sourceforge.net/index.shtml). The Genome Analysis Toolkit was
used to recalibrate base quality scores, perform local realignments
around indels and to call and ﬁlter the variants (McKenna et al.,
2010). VCFtools was used to annotate gene information for the
remaining novel variants. We used ANNOVAR software to annotate
the variants (Wang et al., 2010). Variants were checked against
established databases (1000 Genomes Project and dbSNP v.134).
The protein coding effects of variants were predicted using SIFT,
Polyphen2, and SeattleSeq Annotation (gvs.gs.washington.edu/
SeattleSeqAnnotation). All variants within the coding regions of
APP, PSEN1, PSEN2, MAPT, GRN, and PRNP were annotated for both
cases and controls.
2.4. Sanger sequencing
All rare variants identiﬁed by whole exome sequencing in the
candidate genes were validated by Sanger sequencing.
Primers for exons harboring rare variants were designed in
Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/) using UCSC (http://
genome.ucsc.edu/) reference sequences NM_000484.3 (APP),
NM_000021.3 (PSEN1), NM_000447.2 (PSEN2), NM_001123066.3
(MAPT), NM_002087.2 (GRN), and NM_000311.3 (PRNP).
Puriﬁed sequences were analyzed on an ABI 3730 DNA Analyzer
(Applied Biosystems, CA, USA) and electropherograms were visu-
alized in Sequencher software (version 4.2 Gene Codes Corporation,
MI, USA).
2.5. Apoe genotyping
APOE genotypes comprising the APOE 32, 3 , and 34 alleles were
assayed using the TaqMan method (Applied Biosystems Inc [ABI],
Foster City, CA, USA). SNP-speciﬁc primers and probes were
designed by ABI (TaqMan genotyping assays).
3. Results
We identiﬁed 226 variants (nonsynonymous, synonymous,
intronic, and UTRs) and 18 indels (coding and intronic) in the genes
studied. Of these, we analyzed the 18 rare coding variants (minor
allele frequency <1%), 1 splice-site mutation (MAPT c.115e2A>T),
1 low frequency and 1 common coding polymorphisms in PRNP: a
24 bp deletion (rs138688873) and the p.M129V (rs1799990),
respectively. In our cohort, 14 LOAD cases (10%) and 11 controls (6%)
carryat least oneof these rare variants (Table 2).Wedetected5novel
variants: 3 present in cases (APP p.Y538H, PSEN1 p.I168T, andMAPT
c.115-2A>T) and 2 in controls (MAPT p.G200E and PRNP p.M134V).
PRNP and APP harbor an higher relative proportion of rare cod-
ing variants in controls (1.3/Kb and 1.2/Kb, respectively), compared
to cases (0/Kb and 0.4/Kb, respectively), thus, suggesting that rare
coding variability in these genes may be well tolerated (Table 3). Onategy Age (y) mean  SD (range) Male (%) APOE e4þ (%)
cing 76.7 (65e97) 42 62
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Table 3
Relative frequency of rare variants (rare variants for Kb of coding sequence) in late-
onset AD (LOAD) cases and controls (CTRLS) in APP, PSEN1, PSEN2, MAPT, GRN, PRNP
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gesting that an amino acid change in PS1 is frequently pathogenic.
In our LOAD cohort, we identiﬁed a total of 9 rare coding var-
iants in APP, PSEN1, PSEN2, MAPT, GRN, and PRNP, absent in con-
trols. Of these, 2 are likely to be pathogenic, one in PSEN1 (p.I168T)
and the other in PSEN2 (p.A237V). In contrast, the variants
detected in APP, GRN, MAPT, and PRNP are likely tolerated
polymorphisms.
Several lines of evidence suggest that p.I168T in PSEN1 is a
deleterious change. First, it clusters in the third transmembrane
domain (TM3), on the alpha helix surface, where all the known
pathogenic variants have been reported (alpha-helix rule)
(Hardy and Crook, 2001). Second, a 4 bp inframe deletion
(g.38798_38800delTAT, DI167; DI168) has already been described
in a British family with early-onset Alzheimer’s disease (Janssen
et al., 2003). The patient carrying this variant (PSEN1 p.I168T)
was diagnosed at 86 years of age, heterozygous for APOE ε4 allele
(ε2ε4), presented an advanced Alzheimer’s disease (Braak V), and
did not report any positive family history.
The PSEN2 p.A237V has been only recently reported by the
ClinSeq pilot study (Biesecker et al., 2009) and is likely to be a
functional variant with a probable deleterious effect. It clusters on
the alpha helix surface of the ﬁfth transmembrane domain (TM5),
corresponds to a conserved residue among different species and
in PSEN1 (p.A231), where 2 causative mutations (p.A231V and
p.A231T) have been described in a Dutch, French and Canadian
family (Campion et al., 1999; Cruts et al., 1998; Rogaeva et al., 2001).
The patient carrying the p.A237V variant was diagnosed at 87 years,
homozygous for APOE ε3 allele, and did not refer any family history
of AD.
The other variants detected in our cohort in PSEN2 (p.R62C,
p.R62H, p.S130L, and p.D439A) do not cluster in any TM domain. In
addition, the p.S130L and p.D439A have been found also controls.
GRN harbors 4 missense mutations (p.A324T, p.R432C, p.R433W,
and p.A582T), 2 of which have only been detected in cases (p.R432C
and p.R433W). Although the p.R432C variant has been already
associated with familial FTD and clinical AD (Brouwers et al., 2008;
Cruchaga et al., 2012; Shankaran et al., 2008), its pathogenic role
remains unclear. By contrast, the p.R433W has been reported as a
nonpathogenic variant (www.molgendatabase).
The variants detected in MAPT (c.115-2A>T, p.V224G, p.G213R
and p.G200E) cluster outside the microtubule binding domain,
where most of the pathogenic mutations have been reported up to
date (www.molgendatabase). The c.115-2A>T is predicted to alter
Tau exon 7 splicing, introducing a nonsense codon within exon 11.
We have not detected any difference in exon 7 and in MAPT
expression between the splice-site mutation carrier and the other
cases and controls. Thus, these ﬁndings suggest that c.115-2A>T is
not disease related (Supplementary data).
TheMAPT p.G213R has been found in 2 cases and is absent from
the controls. It has been described as possibly damaging by in silico
predictions and clusters close to a pivotal phosphorylation site
(S214) for the serum and glucocorticoid inducible kinase 1 (SGK1).SGK1 controls neurite outgrowth by depolarizing the microtubules
through the serine phosphorylation at codon 214 (Yang et al., 2006).
Two cases and no controls carry a 24 bp deletion in the PRNP
open reading frame (rs138688873), between the repeat 3 (R3) and
repeat 4 (R4). This octapeptide deletion (rs138688873) has
been described as a risk factor for neurodegenerative diseases
with some controversy (Palmer et al., 1993; Perry et al., 1995).
Furthermore, although these 2 patients were homozygous for
PRNP p.M129M, a common polymorphism and risk factor for
sporadic Creutzfeldt-Jakob disease (sCJD) (Palmer et al., 1991),
p.M129M was not signiﬁcantly associated with AD in this study
(p-value ¼ 0.22, OR ¼ 0.75). Thus, suggesting this common variant
may be a benign polymorphism.
Finally, we report a signiﬁcant association between APOE ε4
allele and LOAD in our cohort (p-value ¼ 0.0002, OR ¼ 2.4).
Nevertheless, we have not detected any enrichment for the APOE ε4
allele among the patients carrying rare variants in APP, PSEN1,
PSEN2, GRN,MAPT, and PRNP (only 6 of 14 LOAD carriers [42%] carry
at least one APOE ε4 allele). By contrast, APOE ε2 allele did not
present a signiﬁcantly higher frequency in controls compared to
cases (p-value ¼ 0.3, OR ¼ 0.66).
4. Discussion
In this study, we tested the hypothesis that the signiﬁcant
phenotypic overlap between sporadic LOAD and other neurode-
generative dementias (FAD, FTD, PSP, CBD, and CJD) may be
explained by a common genetic background. Thus, we screened 6
Mendelian dementia genes (APP, PSEN1, PSEN2, MAPT, GRN, and
PRNP) aiming to establish whether rare coding variability in these
genes is responsible for an appreciable portion of the LOAD risk.
In our LOAD cohort, we found a novel rare variant in PSEN1
(p.I168T) and a rare variant in PSEN2 (p.A237V). These variants are
likely pathogenic: (1) both cluster in TM domains, on the alpha
helix surface; (2) the literature already reported in the same
(PSEN1 p.I168) or homologous residue (PSEN2 p.A237 and PSEN1
p.A231) causative mutations for FAD; and (3) the PSEN1 p.I168T
and PSEN2 p.A237V are classiﬁed as possible pathogenic, following
the algorithm proposed by Guerreiro et al. (2010a). The other
variants detected in our LOAD cases are likely to be tolerated. First,
they have already been described as benign polymorphisms
(PSEN2 p.R62H; PRNP rs138688873 and GRN p.R433W) (Guerreiro
et al., 2010a; Palmer et al., 1993; www.molgendatabase). Second,
they cluster outside the reported pathogenic domains (APP
p.A201V, p.Y538H, p.V562I, p.E599K; PSEN2 p.R62C, p.R62H,
p.S130L, p.D439A; MAPT p.V224G, p.G213R and p.G200E). Third,
they do not alter the gene expression (MAPT c.115-2A>T).
Finally, despite the functional consequence of GRN p.R432C, the
effect of a decreased GRN secretion in AD pathogenesis remains
controversial. GRN pathogenic mutations act through a messenger
RNA nonsense-mediate decay, interfering with GRN expression and
generally are loss of function mutations (LoF) (stop-gain, frameshift
mutations, and deletions). The only exception to this rule is
represented by the pathogenic missense mutations which cluster
in the GRN signal peptide domain (GRN p.A9D) (www.
molgendatabase). Thus, we suggest, in concert with previous
studies (Guerreiro et al., 2010b), that GRN missense mutations
mapping outside the signal peptide domain are likely to be well
tolerated.
In conclusion, our ﬁndings support recent studies, suggesting
that rare coding variability in PSEN1 and PSEN2 contributes to
susceptibility for apparently sporadic LOAD. Therefore, sporadic
LOAD and FAD may be inﬂuenced by the same genes and thus
pathogenic mechanisms. On the contrary, rare coding variants in
MAPT, GRN, and PRNP are not major players in the development of
C. Sassi et al. / Neurobiology of Aging 35 (2014) 2881.e1e2881.e6 2881.e5LOAD. Thus, genetic screening is fundamental for the differential
diagnosis of these disparate neurodegenerative dementias.Acknowledgements
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